David Hirst

David Hirst is a notable inventor based in Northern Ireland, GB. He has made significant contributions to the field of biotechnology, particularly in the area of angiogenesis and its implications in cancer treatment. With a total of 2 patents, Hirst's work focuses on innovative methods and compositions that can potentially transform therapeutic approaches to cancer and related disorders.

Latest Patents

Hirst's latest patents include groundbreaking research on FKBP-L polypeptides. The first patent, titled "FKBP-L polypeptides and uses in angiogenesis-mediated disorders," discloses methods and compositions that utilize FKBP-L polypeptides for modulating angiogenesis and tumor metastasis. This research highlights the potential of FKBP-L polypeptides in treating disorders mediated by angiogenesis, such as cancer. The second patent, "FKBP-L and uses thereof," reiterates similar findings, emphasizing the importance of FKBP-L polypeptides in therapeutic applications.

Career Highlights

David Hirst is currently associated with Almac Discovery Limited, where he continues to advance his research in biotechnology. His work has garnered attention for its innovative approach to addressing complex medical challenges. Hirst's dedication to his field is evident in his ongoing research and development efforts.

Collaborations

Hirst collaborates with talented professionals in his field, including Tracy Robson and Andrea Valentine. These partnerships enhance the research environment and contribute to the advancement of their collective goals in biotechnology.

Conclusion

David Hirst stands out as an influential inventor in the realm of angiogenesis research. His patents and ongoing work at Almac Discovery Limited reflect his commitment to developing innovative solutions for cancer treatment. His contributions are paving the way for future advancements in medical science.

Profile summary based on public USPTO records.